Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

BONE MORPHOGENETIC PROTEINS IN CLINICAL APPLICATIONS

BONE MORPHOGENETIC PROTEINS IN CLINICAL APPLICATIONS The role of bone morphogenetic proteins (BMPs) in bone healing has been shown in numerous animal models. To date, at least 20 BMPs have been identified, some of which have been shown in vitro to stimulate the process of stem cell differentiation into osteoblasts in human and animal models. Having realized the osteoinductive properties of BMPs and having identified their genetic sequences, recombinant gene technology has been used to produce BMPs for clinical application – most commonly, as alternatives or adjuncts in the treatment of cases in which fracture healing is compromised. BMP‐2 and BMP‐7 are approved for clinical use in open fractures of long bones, non‐unions and spinal fusion. However, despite significant evidence of their potential benefit to bone repair and regeneration in animal and preclinical studies, there is, to date, a dearth of convincing clinical trials. The purpose of this paper is to give a brief overview of BMPs and to critically review the clinical data currently available on the use of BMP‐2 and BMP‐7 in fracture healing. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Anz Journal of Surgery Wiley

BONE MORPHOGENETIC PROTEINS IN CLINICAL APPLICATIONS

Loading next page...
 
/lp/wiley/bone-morphogenetic-proteins-in-clinical-applications-Bfwfqqr0v0

References (80)

Publisher
Wiley
Copyright
Copyright © 2007 Wiley Subscription Services, Inc., A Wiley Company
ISSN
1445-1433
eISSN
1445-2197
DOI
10.1111/j.1445-2197.2007.04175.x
pmid
17635273
Publisher site
See Article on Publisher Site

Abstract

The role of bone morphogenetic proteins (BMPs) in bone healing has been shown in numerous animal models. To date, at least 20 BMPs have been identified, some of which have been shown in vitro to stimulate the process of stem cell differentiation into osteoblasts in human and animal models. Having realized the osteoinductive properties of BMPs and having identified their genetic sequences, recombinant gene technology has been used to produce BMPs for clinical application – most commonly, as alternatives or adjuncts in the treatment of cases in which fracture healing is compromised. BMP‐2 and BMP‐7 are approved for clinical use in open fractures of long bones, non‐unions and spinal fusion. However, despite significant evidence of their potential benefit to bone repair and regeneration in animal and preclinical studies, there is, to date, a dearth of convincing clinical trials. The purpose of this paper is to give a brief overview of BMPs and to critically review the clinical data currently available on the use of BMP‐2 and BMP‐7 in fracture healing.

Journal

Anz Journal of SurgeryWiley

Published: Aug 1, 2007

There are no references for this article.